Quality Assurance Initiative on the Therapy of Bladder Cancer 2023
- Conditions
- C67Malignant neoplasm of bladder
- Registration Number
- DRKS00032582
- Lead Sponsor
- Arbeitsgemeinschaft Urologische Onkologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 1639
Inclusion Criteria
Diagnosis of non-muscle-invasive (NMIBC; T<2 N0), muscle-invasive (MIBC; T=2 or N>0) or metastatic (mUC, M>0) bladder carcinoma in Q4/2022-Q1/2023.
Exclusion Criteria
none
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Implementation of the guideline recommendations in routine treatment
- Secondary Outcome Measures
Name Time Method The demographic and clinical characteristics of patients without cancer-specific treatment (best supportive care).